Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
Ludwig Enterprises (OTC PINK:LUDG) has filed a provisional patent for a novel cancer detection method called 'mRNAs Differentially Expressed in Cancer.' The breakthrough technology uses a six-mRNA gene combination that shows enhanced sensitivity and specificity in breast cancer detection. The development is based on research involving over 3,300 cheek cell samples from 40 U.S. medical centers, where AI analyzed more than 12 million combinations of a 48-gene mRNA microarray. The company plans to rebrand as Revealia™ in 2024, subject to regulatory approvals.
Ludwig Enterprises (OTC PINK:LUDG) ha presentato una domanda di brevetto provvisorio per un nuovo metodo di rilevamento del cancro chiamato 'mRNA Espressi Differenzialmente nel Cancro.' Questa tecnologia innovativa utilizza una combinazione di sei mRNA che mostra una maggiore sensibilità e specificità nel rilevamento del cancro al seno. Lo sviluppo si basa su ricerche che coinvolgono oltre 3.300 campioni di cellule buccali provenienti da 40 centri medici negli Stati Uniti, dove l'IA ha analizzato oltre 12 milioni di combinazioni di una microarray di mRNA a 48 geni. L'azienda prevede di cambiare nome in Revealia™ nel 2024, soggetto ad approvazioni regolatorie.
Ludwig Enterprises (OTC PINK:LUDG) ha presentado una patente provisional para un nuevo método de detección del cáncer llamado 'mARN Expresados de Manera Diferencial en Cáncer.' Esta tecnología innovadora utiliza una combinación de seis mARN que muestra una mayor sensibilidad y especificidad en la detección del cáncer de mama. El desarrollo se basa en investigaciones que involucraron más de 3,300 muestras de células bucales de 40 centros médicos en EE. UU., donde la IA analizó más de 12 millones de combinaciones de un microarray de mARN de 48 genes. La empresa planea cambiar de marca a Revealia™ en 2024, sujeto a aprobaciones regulatorias.
루드윅 엔터프라이즈(OTC PINK:LUDG)는 '암에서 차별적으로 발현되는 mRNA'라는 새로운 암 검출 방법에 대한 임시 특허를 출원했습니다. 이 혁신적인 기술은 유방암 검출에서 향상된 민감도와 특이성을 보여주는 6개의 mRNA 유전자 조합을 사용합니다. 이 개발은 40개의 미국 의료 센터에서 3,300개 이상의 뺨 세포 샘플을 포함한 연구를 기반으로 하며, AI는 4800개의 유전자로 구성된 mRNA 마이크로어레이의 1,200만 개 이상의 조합을 분석했습니다. 이 회사는 2024년에 규제 승인을 받는 대로 Revealia™로 브랜드를 변경할 계획입니다.
Ludwig Enterprises (OTC PINK:LUDG) a déposé un brevet provisoire pour une nouvelle méthode de détection du cancer appelée 'mARN Exprimés Différemment dans le Cancer.' Cette technologie révolutionnaire utilise une combinaison de six mARN qui montre une sensibilité et une spécificité accrues dans la détection du cancer du sein. Le développement est basé sur des recherches impliquant plus de 3 300 échantillons de cellules buccales provenant de 40 centres médicaux aux États-Unis, où l'IA a analysé plus de 12 millions de combinaisons d'un microarray d'mARN de 48 gènes. L'entreprise prévoit de se renommer Revealia™ en 2024, sous réserve d'approbations réglementaires.
Ludwig Enterprises (OTC PINK:LUDG) hat ein vorläufiges Patent für eine neuartige Methode zur Krebsdiagnose mit dem Namen 'Differenziell in Krebs exprimierte mRNAs' eingereicht. Diese bahnbrechende Technologie nutzt eine Kombination aus sechs mRNAs, die eine verbesserte Sensitivität und Spezifität bei der Erkennung von Brustkrebs zeigt. Die Entwicklung basiert auf Forschungen mit über 3.300 Wangenzellen-Proben aus 40 medizinischen Zentren in den USA, bei denen KI mehr als 12 Millionen Kombinationen eines mRNA-Mikroarrays mit 48 Genen analysiert hat. Das Unternehmen plant, sich 2024, vorbehaltlich der behördlichen Genehmigungen, in Revealia™ umzubenennen.
- Filed provisional patent for new cancer detection method
- Demonstrated improved sensitivity and specificity in breast cancer detection
- Extensive research base with 3,300+ patient samples from 40 medical centers
- Pending regulatory approvals required for company rebranding
- Early-stage technology without proven commercial success
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has filed a provisional patent for its breakthrough cancer detection method titled "mRNAs Differentially Expressed in Cancer." The company's latest innovation, which analyzes a six-mRNA gene combination, has demonstrated a significant increase in sensitivity and specificity for breast cancer detection, compared to previous methods. "We were already doing well, but this is an incredible performance the likes of which we haven't seen in the genetic breast cancer screening test market," stated Marvin S. Hausman MD, CSO. Our innovative and non-invasive screening test empowers people to be proactive with their medical care, and potentially detect health issues early on."
This advancement emerges from extensive research involving over 3,300 cheek cell samples collected from patients across 40 U.S. medical centers, where proprietary machine learning AI technology analyzed more than 12 million combinations of the company's 48-gene mRNA microarray.
In conjunction with this breakthrough, the company announced plans to rename itself as Revealia™, Inc., pending regulatory approvals and a corresponding ticker symbol change.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to prevent chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than
For more information please visit: http://www.ludwigent.com. www.revealia.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: LUDG_inc
Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com
SOURCE: Ludwig Enterprise, Inc.
View the original press release on accesswire.com
FAQ
What is Ludwig Enterprises' new cancer detection patent about?
How many patient samples were used in Ludwig Enterprises' cancer detection research?
When will Ludwig Enterprises change its name to Revealia?
